| |
Cellular Engineering
While chemotherapy is currently the mainstay of cancer treatment, it is widely recognized that adjunctive biotherapy has the potential to contribute significantly to further improvements in cancer treatment. Stephan Ladisch, MD has proposed that alterations in tumor cell ganglioside metabolism, rendering them susceptible to host destruction, may constitute a novel approach to cancer treatment. His group is developing this model using cell surface gangliosides as the target molecules. Pharmacological and molecular genetic strategies to alter ganglioside metabolism have resulted in findings of markedly reduced tumor formation by modified cells, thus providing the basis for considering application of these strategies to experimental cancer therapy. Studies aimed at pharmacologic modulation of ganglioside metabolism are being conducted in collaboration with Genzyme, Corp.
For more information contact:
Stephan Ladisch, MD
Vice Chair for
External Affairs, Department of Pediatrics
Children's Research Institute
Center for Cancer and Immunology Research
Children's National Medical Center
111 Michigan Avenue, NW
Washington, DC 20010
202-476-3898
202-476-3929 fax
sladisch@cnmc.org
|
|
